Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Efficacy and Safety of Intravitreal Bevacizumab for Threshold ROP.

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified October 2012 by Sivakami A Pai, Dubai Health Authority.
Recruitment status was:  Recruiting
Information provided by (Responsible Party):
Sivakami A Pai, Dubai Health Authority Identifier:
First received: September 22, 2012
Last updated: October 15, 2012
Last verified: October 2012

Prospective study to evaluate the efficacy and safety of intravitreal bevacizumab In retinopathy of prematurity (ROP).

Bevacizumab 0.75 mg in 0.03 ml was given to stage 2+ or stage 3+ ROP in Zone I or Zone II.

Condition Intervention
Stage 2+ or Stage 3+ Retinopathy of Prematurity in Zone I or Zone II.
Procedure: Intravitreal Bevacizumab

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Sivakami A Pai, Dubai Health Authority:

Primary Outcome Measures:
  • Regression Of ROP [ Time Frame: Minimum 6 months follow up after intravitreal Avastin ]

Secondary Outcome Measures:
  • Recurrence of ROP [ Time Frame: minimum 6 months of follow up. ]

Estimated Enrollment: 50
Study Start Date: January 2010
Estimated Study Completion Date: December 2012
Estimated Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Bevacizumab(Avastin) 0.75mg in 0.03 ml
Procedure: Intravitreal Bevacizumab
Other Name: Intravitreal Avastin


Ages Eligible for Study:   32 Weeks to 42 Weeks   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria: stage 2+ or stage 3+ Retinopathy of prematurity in Zone I or Zone II.

Informed written consent by parents or guardian.

Exclusion Criteria:

Refusal to give consent Critically ill neonates.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01707745

Contact: Sivakami A Pai, MS, DNB, Phd 00971504148256
Contact: M A Dekhain, FRCS, MRCOpth 0097142195000 ext 6272

United Arab Emirates
Dubai Hospital Recruiting
Dubai, UAE, United Arab Emirates
Contact: Sivakami A Pai, MS, DNB, Phd    00971504148256      
Contact: Moza A Dekhain, MRCOpthal, FRCS    009712195000 ext 6272   
Principal Investigator: Sivakami A Pai, MS, DNB, Phd         
Sub-Investigator: Afra M Lootah, MSc, FRCS         
Sponsors and Collaborators
Sivakami A Pai
  More Information

Responsible Party: Sivakami A Pai, Doctor, Dubai Health Authority Identifier: NCT01707745     History of Changes
Other Study ID Numbers: Avastin for threshold ROP.
Study First Received: September 22, 2012
Last Updated: October 15, 2012

Additional relevant MeSH terms:
Retinopathy of Prematurity
Retinal Diseases
Eye Diseases
Infant, Premature, Diseases
Infant, Newborn, Diseases
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents processed this record on May 25, 2017